Chris Fiore
Cégep de Saint-Laurent(CA)
Publications by Year
Research Areas
Retinoids in leukemia and cellular processes, Click Chemistry and Applications, Advanced biosensing and bioanalysis techniques, Protein Degradation and Inhibitors, Acute Myeloid Leukemia Research
Most-Cited Works
- → Conserved role of intragenic DNA methylation in regulating alternative promoters(2010)1,755 cited
- → Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist(2017)135 cited
- → Chromatin Accessibility Mapping of Primary Erythroid Cell Populations Leads to Identification and Validation of Nuclear Factor I X (NFIX) As a Novel Fetal Hemoglobin (HbF) Repressor(2019)3 cited
- → Abstract P6-11-18: A novel subgroup of estrogen receptor positive breast cancer may benefit from super-enhancer guided patient selection for retinoic acid receptor α agonist treatment(2017)
- → Enhancing Technology Transfer on University Campuses Through Trainee-Led Grassroots Efforts: A Case Study of The BALSA Group and Fourth River Solutions(2015)
- → Supplementary Table S2: mRNA Cluster Signatures from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist(2023)
- → Supplementary Table S3: Median Survival By Cluster from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist(2023)
- → Supplementary Table S5 & 6: GSEA of SY-1425 response from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist(2023)
- → Supplementary Table S7: GREAT analysis from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist(2023)